Skip to main content
SpringerLink
Log in
Book cover

Psychiatry for Neurologists pp 177–189Cite as

Neuropsychiatric Disorders in Multiple Sclerosis

  • Chapter

  • 1403 Accesses

Part of the book series: Current Clinical Neurology ((CCNEU))

Abstract

In this chapter, we review the empirical literature on the epidemiology, etiology, consequences, and treatment of neuropsychiatric disturbance associated with multiple sclerosis (MS). We focus primarily on depression and neuropsychological impairment, as most of the empirical literature examined these two areas. However, we briefly describe other areas including pathological laughing and crying (PLC), anxiety, anger, and bipolar disorder.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Andersson P-B, Goodkin DE. Current pharmacologic treatment of multiple sclerosis symptoms. West J Med 1996;165:313–317.

    PubMed  CAS  Google Scholar 

  2. Schapiro RT. Symptom management in multiple sclerosis. Ann Neurol 1994;36(Suppl):S123–S129.

    PubMed  Google Scholar 

  3. Thompson AJ. Multiple sclerosis: symptomatic treatment. J Neurol 1996;243:559–565.

    PubMed  CAS  Google Scholar 

  4. Patten SB, Beck CA, Williams JV, Barbui C, Metz LM. Major depression in multiple sclerosis: a population-based perspective. Neurology 2003;61:1524–1527.

    PubMed  CAS  Google Scholar 

  5. Chwastiak L, Ehde DM, Gibbons LE, Sullivan M, Bowen JD, Kraft GH. Depressive symptoms and severity of illness in multiple sclerosis: epidemiologic study of a large community sample. Am J Psychiatry 2002;159:1862–1868.

    PubMed  Google Scholar 

  6. Sadovnick AD, Remick RA, Allen J, et al. Depression and multiple sclerosis. Neurology 1996;46:628–632.

    PubMed  CAS  Google Scholar 

  7. Minden SL, Orav J, Reich P. Depression in multiple sclerosis. Gen Hosp Psychiatry 1987;9:426–434.

    PubMed  CAS  Google Scholar 

  8. Surridge D. An investigation into some psychiatric aspects of multiple sclerosis. Br J Psychiatry 1969;115:749–764.

    PubMed  CAS  Google Scholar 

  9. Rabins PV, Brooks BR, O’Donnell P, et al. Structural brain correlates of emotional disorder in multiple sclerosis. Brain 1986;109:585–597.

    PubMed  Google Scholar 

  10. Whitlock FA, Siskind MM. Depression as a major symptom of multiple sclerosis. J Neurol Neurosurg Psychiatry 1980;43:861–865.

    PubMed  CAS  Google Scholar 

  11. Mohr DC, Goodkin DE. Treatment of depression in multiple sclerosis: review and meta-analysis. Clin Psychol Sci Prac 1999;6:1–9.

    Google Scholar 

  12. McIvor GP, Riklan M, Reznikoff M. Depression in multiple sclerosis as a function of length and severity of illness, age, remissions, and perceived social support. J Clinical Psychol 1984;40:1028–1033.

    CAS  Google Scholar 

  13. Millefiorini E, Padovani A, Pozzilli C, et al. Depression in the early phase of MS: influence of functional disability, cognitive impairment and brain abnormalities. Acta Neurol Scand 1992;86:354–358.

    PubMed  CAS  Google Scholar 

  14. Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 1991;41:685–691.

    PubMed  CAS  Google Scholar 

  15. Wineman NM, Schwetz KM, Goodkin DE, Rudick RA. Relationships among illness uncertainty, stress, coping, and emotional well-being at entry into a clinical drug trial. Appl Nurs Res 1996;9:53–60.

    PubMed  CAS  Google Scholar 

  16. Schiaffino KM, Shawaryn MA, Blum D. Examining the impact of illness representations on psychological adjustment to chronic illness. Health Psychol 1998;17:262–268.

    PubMed  CAS  Google Scholar 

  17. Devins GM, Edworthy SM, Paul LC, et al. Restless sleep, illness intrusiveness, and depressive symptoms in three chronic illness conditions: rheumatoid arthritis, end-stage renal disease, and multiple sclerosis. J Psychosom Res 1993;37:163–170.

    PubMed  CAS  Google Scholar 

  18. Devins GM, Edworthy SM, Seland TP, Klein GM, Paul LC, Mandin H. Differences in illness intrusiveness across rheumatoid arthritis, end-stage renal disease, and multiple sclerosis. J Nerv Ment Dis 1993;181:377–381.

    PubMed  CAS  Google Scholar 

  19. Devins GM, Styra R, O’Connor P, et al. Psychosocial impact of illness intrusiveness moderated by age in multiple sclerosis. Psychology, Health, and Medicine 1996;1:179–191.

    Google Scholar 

  20. Barnwell AM, Kavanagh DJ. Prediction of psychological adjustment to multiple sclerosis. Soc Sci Med 1997;45:411–418.

    PubMed  CAS  Google Scholar 

  21. Gilchrist AC, Creed FH. Depression, cognitive impairment and social stress in multiple sclerosis. J Psychosom Res 1994;38:193–201.

    PubMed  CAS  Google Scholar 

  22. Gulick EE. Correlates of quality of life among persons with multiple sclerosis. Nurs Res 1997;46:305–311.

    PubMed  CAS  Google Scholar 

  23. Pakenham KI. Adjustment to multiple sclerosis: application of a stress and coping model. Health Psychol 1999;18:383–392.

    PubMed  CAS  Google Scholar 

  24. Feinstein A, Roy P, Lobaugh N, Feinstein K, O’Connor P, Black S. Structural brain abnormalities in multiple sclerosis patients with major depression. Neurology 2004;62:586–590.

    PubMed  CAS  Google Scholar 

  25. Zorzon M, Zivadinov R, Nasuelli D, et al. Depressive symptoms and MRI changes in multiple sclerosis. Eur J Neurol 2002;9:491–496.

    PubMed  CAS  Google Scholar 

  26. Bakshi R, Czarnecki D, Shaikh ZA, et al. Brain MRI lesions and atrophy are related to depression in multiple sclerosis. Neuroreport 2000;11:1153–1158.

    PubMed  CAS  Google Scholar 

  27. Capuron L, Dantzer R. Cytokines and depression: the need for a new paradigm. Brain Behav Immun 2003;17(Suppl 1):S119–S124.

    PubMed  CAS  Google Scholar 

  28. Dalos NP, Rabins PV, Brooks BR, O’Donnell P. Disease activity and emotional state in multiple sclerosis. Ann Neurol 1983;13:573–577.

    PubMed  CAS  Google Scholar 

  29. Fassbender K, Schmidt R, Mossner R, et al. Mood disorders and dysfunction of the hypothalamic-pituitary-adrenal axis in multiple sclerosis: association with cerebral inflammation. Arch Neurol 1998;55:66–72.

    PubMed  CAS  Google Scholar 

  30. Medical Economics. Physicians’ Desk Reference, Fifty Second Edition. Montvale, NJ: Medical Economics Data Production Company; 1998.

    Google Scholar 

  31. Mohr DC, Goodkin DE, Likosky W, et al. Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-1b: relationship to adherence to treatment. Mult Scler 1996;2:222–226.

    PubMed  CAS  Google Scholar 

  32. Mohr DC, Likosky W, Boudewyn AC, et al. Side effect profile and adherence to in the treatment of multiple sclerosis with interferon beta-1a. Mult Scler 1998;4:487–489.

    PubMed  CAS  Google Scholar 

  33. Neilley LK, Goodin DS, Goodkin DE, Hauser SL. Side effect profile of interferon beta-1b in MS: results of an open label trial. Neurology 1996;46:552–554.

    PubMed  CAS  Google Scholar 

  34. Borràs C, Río J, Porcel J, Barrios M, Tintoré M, Montalbon X. Emotional state of patients with relapsing-remitting MS treated with interferon beta-1b. Neurology 1999;52:1636–1639.

    PubMed  Google Scholar 

  35. Feinstein A, O’Connor P, Feinstein K. Multiple sclerosis, interferon beta-1b and depression: a prospective investigation. J Neurol 2002;249:815–820.

    PubMed  Google Scholar 

  36. Mohr DC, Likosky W, Dwyer P, Van Der Wende J, Boudewyn AC, Goodkin DE. Course of depression during the initiation of interferon beta-1a treatment for multiple sclerosis. Arch Neurol 1999;56:1263–1265.

    PubMed  CAS  Google Scholar 

  37. Wineman NM. Adaptation to multiple sclerosis: the role of social support, functional disability, and perceived uncertainty. Nurs Res 1990;39:294–299.

    PubMed  CAS  Google Scholar 

  38. Wineman NM, Durand EJ, McCulloch BJ. Examination of the factor structure of the Ways of Coping Questionnaire with clinical populations. Nurs Res 1994;43:268–273.

    PubMed  CAS  Google Scholar 

  39. Maurelli M, Marchioni E, Cerretano R, et al. Neuropsychological assessment in MS: clinical neuropsychological and neuroreadiological relationships. Acta Neurol Scand 1992;86:124–128.

    PubMed  CAS  Google Scholar 

  40. Minden SL, Schiffer RB. Mood disorders in multiple sclerosis. Neuropsychiatry Neuropsychol Behav Neuro 1991;4:62–77.

    Google Scholar 

  41. Pepper CM, Krupp LB, Friedberg F, Doscher C, Coyle PK. A comparison of neuropsychiatric characteristics in chronic fatigue syndrome, multiple sclerosis, and major depression. J Neuropsychiatry Clin Neurosci 1993;5:200–205.

    PubMed  CAS  Google Scholar 

  42. Stenager E, Knudsen L, Jensen K. Multiple sclerosis: correlation of anxiety, physical impairment and cognitive dysfunction. Ital J Neurol Sci 1994;15:97–101.

    PubMed  CAS  Google Scholar 

  43. Feinstein A, O’Connor P, Gray T, Feinstein K. The effects of anxiety on psychiatric morbidity in patients with multiple sclerosis. Mult Scler 1999;5:323–326.

    PubMed  CAS  Google Scholar 

  44. Mohr DC, Cox D. Managing difficulties with adherence to injectable medications due to blood, injection, and injury phobia and self-injection anxiety. Am J Drug Deliv 2003;1:215–221.

    Google Scholar 

  45. Minden SL. Psychotherapy for people with multiple sclerosis. Neuropsychiatry 1992;4:198–213.

    CAS  Google Scholar 

  46. Mohr DC, Cox D. Multiple Sclerosis. Clinical Handbook of Health Psychology: A Practical Guide to Effective Interventions, Second Edition. USA: Hogrefe and Huber; 2004.

    Google Scholar 

  47. Poeck K. Pathophysiology of emotional disorders associated with brain damage. In:Vinken PJ, Bruyn GW, eds. Handbook of Clinical Neurology. Amsterdam: North Holland Publishing; 1969:343–367.

    Google Scholar 

  48. Feinstein A, Feinstein K, Gray T, O’Connor P. Prevalence of neurobehavioral correlates of pathological laughing and crying in multiple sclerosis. Arch Neurol 1997;54:1116–1121.

    PubMed  CAS  Google Scholar 

  49. Seliger GM, Hornstein A, Flax J, Herbert J, Schroeder K. Fluoxetine improved emotional incontinence. Brain Inj 1992;6:267–270.

    PubMed  CAS  Google Scholar 

  50. Iannaccone S, Ferini-Strambi L. Pharmacologic treatment of emotional lability. Clin Neuropharmacol 1996;19:532–535.

    PubMed  CAS  Google Scholar 

  51. Kahana E, Leibowitz U, Alter M. Cerebral multiple sclerosis. Neurology 1971;21:1179–1185.

    PubMed  CAS  Google Scholar 

  52. Achiron A, Barak Y. Cognitive impairment in probable multiple sclerosis. J Neurol Neurosurg Psychiatry 2003;74:443–446.

    PubMed  CAS  Google Scholar 

  53. Ruggieri RM, Palermo R, Vitello G, Gennuso M, Settipani N, Piccoli F. Cognitive impairment in patients suffering from relapsing-remitting multiple sclerosis with EDSS < or = 3.5. Acta Neurol Scand 2003;108:323–326.

    PubMed  CAS  Google Scholar 

  54. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, Fourth Edition. Washington DC: Amer Psychiatric Pub; 1994.

    Google Scholar 

  55. Thornton AE, Raz N. Memory impairment in multiple sclerosis: a quantitative review. Neuropsychology 1997;11:357–366.

    PubMed  CAS  Google Scholar 

  56. Zakzanis K. Distinct neurocognitive profiles in multiple sclerosis subtypes. Arch Clin Neuropsychol 2000;15:115–136.

    PubMed  CAS  Google Scholar 

  57. Kujala P, Portin R, Ruutianen J. Memory deficits and early cognitive deterioration in MS. Acta Neurol Scand 1996;93:329–335.

    PubMed  CAS  Google Scholar 

  58. Brassington JC, Marsh NV. Neuropsychological aspects of multiple sclerosis. Neuropsychol Rev 1998;8:43–77.

    PubMed  CAS  Google Scholar 

  59. DeLuca J, Barbieri-Berger S, Johnson SK. The nature of memory impairments in multiple sclerosis: acquisition versus retrieval. Journal of clinical and experimental Neuropsychology 1994;16:183–189.

    PubMed  CAS  Google Scholar 

  60. Rovaris M, Filippi M, Falautano M, et al. Relation between MR abnormalities and patterns of cognitive impairment in multiple sclerosis. Neurology 1998;50:1601–1608.

    PubMed  CAS  Google Scholar 

  61. Camp S, Stevenson V, Thompson A, et al. Cognitive function in primary progressive and transitional progressive multiple sclerosis: a controlled study with MRI correlates. Brain 1999;122:1341–1348.

    PubMed  Google Scholar 

  62. Comi G, Filippi M, Martinelli V, et al. Brain MRI correlates of cognitive impairment in primary and secondary progressive multiple sclerosis. J Neurol Sci 1995;132:222–227.

    PubMed  CAS  Google Scholar 

  63. Foong J, Rozewicz L, Quaghebeur G, et al. Executive function in multiple sclerosis: The role of frontal lobe pathology. Brain 1997;120:15–26.

    PubMed  Google Scholar 

  64. Hohol MJ, Guttmann CR, Orav J, et al. Serial neuropsychological assessment and magnetic resonance imaging analysis in multiple sclerosis. Arch Neurol 1997;54:1018–1025.

    PubMed  CAS  Google Scholar 

  65. Zivadinov R, Sepcic J, Nasuelli D, et al. A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2001;70:773–780.

    PubMed  CAS  Google Scholar 

  66. Edwards S, Liu C, Blumhardt L. Cognitive correlates of supratentorial atrophy on MRI in multiple sclerosis. Acta Neurol Scand 2001;104:214–223.

    PubMed  CAS  Google Scholar 

  67. Benedict R, Bakshi R, Simon JH, Priore R, Miller C, Munschauer F. Frontal cortex atrophy predicts cognitive impairment in multiple sclerosis. J Neuropsychiatry Clin Neurosci 2002;14:44–51.

    PubMed  Google Scholar 

  68. Huber SJ, Rammohan KW, Bornstein RA, Christy JA. Depressive symptoms are not influenced by severity of multiple sclerosis. Neuropsychiatry Neuropsychol Behav Neuro 1993;6:177–180.

    Google Scholar 

  69. Benedict R, Weinstock-Guttman B, Fishman I, Sharma J, Tjoa C, Bakshi R. Prediction of neuropsychological impairment in multiple sclerosis: comparison of conventional magnetic resonance imaging measures of atrophy and lesion burden. Arch Neurol 2004;61:226–230.

    PubMed  Google Scholar 

  70. Cox D, Pelletier D, Genain C, et al. The unique impact of changes in normal appearing brain tissue on cognitive dysfunction in secondary progressive multiple sclerosis patients. Mult Scler 2004;10:626–629.

    PubMed  Google Scholar 

  71. Schiffer RB, Weitkamp LR, Wineman NM, Guttormsen S. Multiple sclerosis and affective disorder. Family history, sex, and HLA-DR antigens. Arch Neurol 1988;45:1345–1348.

    PubMed  CAS  Google Scholar 

  72. Schiffer RB, Wineman NM, Weitkamp LR. Association between bipolar affective disorder and multiple sclerosis. Am J Psychiatry 1986;143:94–95.

    PubMed  CAS  Google Scholar 

  73. Mohr DC, Goodkin DE, Likosky W, Beutler L, Gatto N, Langan MK. Identification of Beck Depression Inventory items related to multiple sclerosis. J Behav Med 1997;20:407–414.

    PubMed  CAS  Google Scholar 

  74. Moran PJ, Mohr DC. The validity of Beck Depression Inventory and Hamilton Rating Scale for Depression items in the assessment of depression among patients with multiple sclerosis. J Behav Med 2005;35–41.

    Google Scholar 

  75. Mohr DC, Hart S, Merluzzi N, Fonareva I, Tasch ES. Depression in Multiple Sclerosis: Screening and Treatment. Under review.

    Google Scholar 

  76. Sullivan MJ, Weinshenker B, Mikail S, Bishop SR. Screening for major depression in the early stages of multiple sclerosis. Can J Neurol Sci 1995;22:228–231.

    PubMed  CAS  Google Scholar 

  77. Whooley MA, Avins AL, Miranda J, Browner WS. Case-finding instruments for depression. Two questions are as good as many. J Gen Intern Med 1997;12:439–445.

    PubMed  CAS  Google Scholar 

  78. Schwartz CE, Kozora E, Zeng Q. Towards patient collaboration in cognitive assessment: Specificity, sensitivity, and incremental validity of self-report. Ann Behav Med 1996;18:177–184.

    Google Scholar 

  79. Benedict RH, Munschauer F, Linn R, et al. Screening for multiple sclerosis cognitive impairment using a self-administered 15-item questionnaire. Mult Scler 2003;9:95–101.

    PubMed  CAS  Google Scholar 

  80. Provinciali L, Ceravolo MG, Bartolini M, Logullo F, Danni M. A multidimensional assessment of multiple sclerosis: relationships between disability domains. Acta Neurol Scand 1999;100:156–162.

    PubMed  CAS  Google Scholar 

  81. Feinstein A. An examination of suicidal intent in patients with multiple sclerosis. Neurology 2002;59:674–678.

    PubMed  Google Scholar 

  82. Sadovnick AD, Eisen K, Ebers GC, Paty DW. Cause of death in patients attending multiple sclerosis clinics. Neurology 1991;41:1193–1196.

    PubMed  CAS  Google Scholar 

  83. Rao SM, Leo GJ, Ellington L, Nauertz T, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis II. Impact on employment and social functioning. Neurology 1991;41:692–696.

    PubMed  CAS  Google Scholar 

  84. Amato M, Ponziani G, Siracusa G, Sorbi S. Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years. Arch Neurol 2001;58:1602–1606.

    PubMed  CAS  Google Scholar 

  85. Scott TF, Allen D, Price TR, McConnell H, Lang D. Characterization of major depression symptoms in multiple sclerosis patients. J Neuropsychiatry Clin Neurosci 1996;8:318–323.

    PubMed  CAS  Google Scholar 

  86. Flax JW, Gray J, Herbert J. Effect of fluoxetine on patients with multiple sclerosis. Am J Psychiatry 1991;148:1603.

    PubMed  CAS  Google Scholar 

  87. Schiffer RB, Wineman NM. Antidepressant pharmacotherapy of depression associated with multiple sclerosis. Am J Psychiatry 1990;147:1493–1497.

    PubMed  CAS  Google Scholar 

  88. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56–62.

    PubMed  CAS  Google Scholar 

  89. Beck AT, Ward CH, Medelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561–571.

    PubMed  CAS  Google Scholar 

  90. Mohr DC, Boudewyn AC, Goodkin DE, Bostrom A, Epstein L. Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis. J Consult Clin Psychol 2001;69:942–949.

    PubMed  CAS  Google Scholar 

  91. Simon GE. Evidence review: efficacy and effectiveness of antidepressant treatment in primary care. Gen Hosp Psychiatry 2002;24:213–224.

    PubMed  Google Scholar 

  92. Munoz RF, Hollon SD, McGrath E, Rehm LP, VandenBos GR. On the AHCPR depression in primary care guidelines. Further considerations for practitioners. Agency for Health Care Policy and Research. AHCPR. Am Psychol 1994;49:42–61.

    CAS  Google Scholar 

  93. Schulberg HC, Block MR, Madonia MJ, et al. The ‘usual care’ of major depression in primary care practice. Arch Fam Med 1997;6:334–339.

    PubMed  CAS  Google Scholar 

  94. Hirschfeld RM, Keller MB, Panico S, et al. The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA 1997;277:333–340.

    PubMed  CAS  Google Scholar 

  95. Simon GE, Lin EH, Katon W, et al. Outcomes of “inadequate” antidepressant treatment. J Gen Intern Med 1995;10:663–70.

    PubMed  CAS  Google Scholar 

  96. Hunkeler EM, Meresman JF, Hargreaves WA, et al. Efficacy of nurse telehealth care and peer support in augmenting treatment of depression in primary care. Arch Fam Med 2000;9:700–8.

    PubMed  CAS  Google Scholar 

  97. Simon GE, VonKorff M, Rutter C, Wagner E. Randomised trial of monitoring, feedback, and management of care by telephone to improve treatment of depression in primary care. BMJ 2000;320:550–554.

    PubMed  CAS  Google Scholar 

  98. Keller MB, McCullough JP, Klein DN, et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med 2000;342:1462–1470.

    PubMed  CAS  Google Scholar 

  99. Mohr DC, Epstein L, Luks TL, et al. Brain lesion volume and neuropsychological function predict efficacy of treatment for depression in multiple sclerosis. J Consult Clin Psychol 2003;71:1017–1024.

    PubMed  Google Scholar 

  100. Elkin I, Gibbons RD, Shea MT, et al. Initial severity and differential treatment outcome in the National Institute of Mental Health Treatment of Depression Collaborative Research Program. J Consult Clin Psychol 1995;63:841–847.

    PubMed  CAS  Google Scholar 

  101. Alexopoulos GS, Kiosses DN, Choi SJ, Murphy CF, Lim KO. Frontal white matter microstructure and treatment response of late-life depression: a preliminary study. Am J Psychiatry 2002;159:1929–1932.

    PubMed  Google Scholar 

  102. Alexopoulos GS, Meyers BS, Young RC, et al. Executive dysfunction and long-term outcomes of geriatric depression. Arch Gen Psychiatry 2000;57:285–290.

    PubMed  CAS  Google Scholar 

  103. Kalayam B, Alexopoulos GS. Prefrontal dysfunction and treatment response in geriatric depression. Arch Gen Psychiatry 1999;56:713–718.

    PubMed  CAS  Google Scholar 

  104. Julian L, Mohr DC. Executive functioning is a differential predictor for response to treatment for depression in multiple sclerosis. Under review.

    Google Scholar 

  105. Fischer JS, Priore R, Jacobs L, et al. Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group. Ann Neurol 2000;48:885–892.

    PubMed  CAS  Google Scholar 

  106. Pliskin N, Hamer D, Goldstein D, et al. Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b. Neurology 1996;47:1463–1468.

    PubMed  CAS  Google Scholar 

  107. Weinstein A, Schwid SIL, Schiffer RB, McDermott MP, Giang DW, Goodman AD. Neuropsychologic status in multiple sclerosis after treatment with glatiramer. Arch Neurol 1999;56:319–324.

    PubMed  CAS  Google Scholar 

  108. Fischer JS, Priore RL, Jacobs LD, et al. Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group. Ann Neurol 2000;48:885–892.

    PubMed  CAS  Google Scholar 

  109. Greene Y, Tariot P, Wishart H, et al. 12-week, open trial of donepezil hydrocholoride in patients with multiple sclerosis and associated cognitive impairments. J Clin Psychopharmacol 2000;20:350–356.

    PubMed  CAS  Google Scholar 

  110. Allyson MMP, Scott RB, Palace J, Smith S, Matthews PM. Potentially adaptive functional changes in cognitive processing for patients with multiple sclerosis and their acute modulation by rivastigmine. Brain 2003;126:2750–2760.

    Google Scholar 

  111. Charcot JM. Lectures on Diseases of the Nervous System. Sigerson G, Translator. London: New Sydenham Society; 1877.

    Google Scholar 

  112. Mohr DC, Hart SL, Julian L, Cox D, Pelletier D. Association between stressful life events and exacerbation in multiple sclerosis: a meta-analysis. BMJ 2004;328:731.

    PubMed  Google Scholar 

  113. Mohr DC, Goodkin DE, Bacchetti P, et al. Psychological stress and the subsequent appearance of new brain MRI lesions in MS. Neurology 2000;55:55–61.

    PubMed  CAS  Google Scholar 

  114. Nisipeanu P, Korczyn AD. Psychological stress as risk factor for exacerbations in multiple sclerosis. Neurology 1993;43:1311–1312.

    PubMed  CAS  Google Scholar 

  115. Mohr DC, Goodkin DE, Likosky W, Gatto N, Baumann KA, Rudick RA. Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Arch Neurol 1997;54:531–533.

    PubMed  CAS  Google Scholar 

  116. Mohr DC, Likosky W, Bertagnolli A, et al. Telephone-administered cognitive-behavioral therapy for the treatment of depressive symptoms in multiple sclerosis. J Consult Clin Psychol 2000;68:356–361.

    PubMed  CAS  Google Scholar 

  117. Bakshi R, Shaikh ZA, Miletich RS, et al. Fatigue in multiple sclerosis and its relationship to depression and neurologic disability. Mult Scler 2000;6:181–185.

    PubMed  CAS  Google Scholar 

  118. Schwartz CE, Coulthard-Morris L, Zeng Q. Psychosocial correlates of fatigue in multiple sclerosis. Arch Phys Med Rehabil 1996;77:165–170.

    PubMed  CAS  Google Scholar 

  119. Mohr DC, Hart SL, Goldberg A. Effects of treatment for depression on fatigue in multiple sclerosis. Psychosom Med 2003;65:542–547.

    PubMed  Google Scholar 

  120. Lu CZ, Jensen MA, Arnason BG. Interferon gamma-and interleukin-4-secreting cells in multiple sclerosis. J Neuroimmunol 1993;46:123–128.

    PubMed  CAS  Google Scholar 

  121. Panitch HS, Hirsch RL, Schindler J, Johnson KP. Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology 1987;37:1097–1102.

    PubMed  CAS  Google Scholar 

  122. Mohr DC, Goodkin DE, Islar J, Hauser SL, Genain CP. Treatment of depression is associated with suppression of nonspecific and antigen-specific T(H)1 responses in multiple sclerosis. Arch Neurol 2001;58:1081–1086.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Neurology and Psychiatry, VA Medical Center, University of California, San Francisco, CA

    David C. Mohr PhD

  2. Department of Neurology, University of California, San Francisco, CA

    Darcy Cox PsyD

Authors
  1. David C. Mohr PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Darcy Cox PsyD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Psychiatry and Neurosciences, University of California, San Diego

    Dilip V. Jests MD

  2. Department of Psychiatry and Neurosciences, VA San Diego Healthcare System, San Diego, CA

    Dilip V. Jests MD

  3. Parkinson’s Disease and Movement Disorders Center, NeuroHealth, Warwick, RI

    Joseph H. Friedman MD

  4. University Medical School, Providence, RI

    Joseph H. Friedman MD

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Mohr, D.C., Cox, D. (2006). Neuropsychiatric Disorders in Multiple Sclerosis. In: Jests, D.V., Friedman, J.H. (eds) Psychiatry for Neurologists. Current Clinical Neurology. Humana Press. https://doi.org/10.1007/978-1-59259-960-8_15

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-960-8_15

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-483-8

  • Online ISBN: 978-1-59259-960-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation